Deferasirox and Vitamin D Improves Overall Survival in Elderly Patients with Acute Myeloid Leukemia after Demethylating Agents Failure

Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia

(2012) Hagop M. Kantarjian et al.   JOURNAL OF CLINICAL ONCOLOGY

Therapeutic Advances in Acute Myeloid Leukemia

(2011) Alan Burnett et al.   JOURNAL OF CLINICAL ONCOLOGY

Deferasirox is a powerful NF- B inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging

(2010) E. Messa et al.   HAEMATOLOGICA

Targeting iron homeostasis induces cellular differentiation and synergizes with differentiating agents in acute myeloid leukemia

(2010) Celine Callens et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM

(2010) Christian Rose et al.   LEUKEMIA RESEARCH

AML in older patients: Are we making progress?

(2009) Elihu Estey   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia

(2009) Pierre Fenaux et al.   JOURNAL OF CLINICAL ONCOLOGY

Vitamin D3-driven signals for myeloid cell differentiation—Implications for differentiation therapy

(2009) Philip J. Hughes et al.   LEUKEMIA RESEARCH

Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation

(2008) Rihab Nasr et al.   NATURE MEDICINE